| VIFOR-FRESENIUS-MEDICAL-CARE-RENAL-PHARMA-LTD |
VIFOR-FRESENIUS-MEDICAL-CARE-RENAL-PHARMA-LTD |
85%
|
rtain renal pharmaceuticals from Vifor Fresenius Medical Care Renal Pharma Ltd., which are used in the Company’s clinics to provide health care services to its patients. The Company’s Global Medical … |
| APAM |
Artisan Partners Asset Management Inc. |
72%
|
e, U.S., with respect to attributed voting rights, disclosed pursuant to Sections 33, 34 of the WpHG that 4.34 % of the voting rights of the Company and pursuant to Section 38 of the WpHG that instru… |
| APAM |
Artisan Partners Asset Management Inc. |
72%
|
Reciprocal relationship from APAM graph: Reciprocal relationship from FMS graph: e, U.S., with respect to attributed voting rights, disclosed pursuant to Sections 33, 34 of the WpHG that 4.34 % of th… |
| CHRS |
Coherus Oncology, Inc. |
72%
|
Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimburs… |
| CTSO |
Cytosorbents Corporation |
72%
|
Reciprocal relationship from CTSO graph: k, and anti-self referral and insurance laws that apply to state-funded Medicaid and other health care programs and private third-party payers and some state … |
| FSNUY |
Fresenius SE & Co. KGaA |
72%
|
tal liabilities and equity 31,002,333 33,566,579 The following notes are an integral part of the consolidated financial statements. F-7 Table of Contents FRESENIUS MEDICAL CARE AG … |
| FSNUY |
Fresenius SE & Co. KGaA |
72%
|
Reciprocal relationship from FSNUY graph: Reciprocal relationship from FMS graph: Reciprocal relationship from FSNUY graph: Reciprocal relationship from FMS graph: Reciprocal relationship from FSNUY … |
| OM |
Outset Medical, Inc. |
72%
|
ified herein, all market patient and other market data in this report has been derived using our internal market analysis tools. According to our estimates, the volume of the global dialysis market r… |
| OM |
Outset Medical, Inc. |
72%
|
Reciprocal relationship from OM graph: bloHub designed for patients who are dialyzing at home or performing self-care at a clinic. Using MyTablo, patients can access training and download their treat… |
| SNYNF |
Sanofi |
72%
|
ified herein, all market patient and other market data in this report has been derived using our internal market analysis tools. According to our estimates, the volume of the global dialysis market r… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from FMS graph: ified herein, all market patient and other market data in this report has been derived using our internal market anal… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
ified herein, all market patient and other market data in this report has been derived using our internal market analysis tools. According to our estimates, the volume of the global dialysis market r… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from FMS graph: ified herein, all market patient and other market data in this report has been derived using our internal market anal… |
| AKEBIA-THERAPEUTICS-INC-BAXTER-INTERNATIONAL-INC |
AKEBIA-THERAPEUTICS-INC-BAXTER-INTERNATIONAL-INC |
62%
|
ified herein, all market patient and other market data in this report has been derived using our internal market analysis tools. According to our estimates, the volume of the global dialysis market r… |
| AKEBIA-THERAPEUTICS-INC-GUANGDONG-BIOLIGHT-MEDIT |
AKEBIA-THERAPEUTICS-INC-GUANGDONG-BIOLIGHT-MEDIT |
62%
|
the accuracy of such information. According to our estimates, the volume of the global dialysis market grew to around €81 to 85 BN in 2025 (2024: €80 to 84 BN). We estimate the following approximate … |
| BESIDES-FME-AG |
BESIDES-FME-AG |
62%
|
ed in other operating income and other operating expense, respectively, within the Company’s consolidated statements of income and within other current and non-current assets within the Company’s con… |
| CARDIOVASCULAR-CONSULTANTS-LTD |
CARDIOVASCULAR-CONSULTANTS-LTD |
62%
|
others in the industry, has engaged in unfair or exclusionary conduct in violation of Section 5 of the FTC Act in the acquisition of Medical Director services or provision of dialysis services. The C… |
| CONVERSION-FRESENIUS-MEDICAL-CARE-MANAGEMENT-AG |
CONVERSION-FRESENIUS-MEDICAL-CARE-MANAGEMENT-AG |
62%
|
. The Company provides administrative services to one of its equity method investees. The Company also sells products to Fresenius SE Companies and purchases products from Fresenius SE Companies and … |
| CRICKET-HEALTH-INC |
CRICKET-HEALTH-INC |
62%
|
ies in which the Company has the majority of the equity ownership and voting rights and does not consolidate, an assessment of materiality is made in order to determine that the subsidiary is insigni… |
| CURA-DAY-HOSPITALS-GROUP |
CURA-DAY-HOSPITALS-GROUP |
62%
|
nd the Cura Day Hospitals Group in Australia in 2024. These strategic actions reinforce our commitment to enhancing operational efficiency and focusing on areas related to our core business. In Care … |
| DIAVERUM-AB-B-BRAUN-SE-U-S-RENAL-CARE-INC |
DIAVERUM-AB-B-BRAUN-SE-U-S-RENAL-CARE-INC |
62%
|
ified herein, all market patient and other market data in this report has been derived using our internal market analysis tools. According to our estimates, the volume of the global dialysis market r… |
| FME-AG |
FME-AG |
62%
|
cipated synergies and future cash flows expected to be generated for these acquisitions. Business combinations during 2024 increased the Company’s net income attributable to shareholders of FME AG (N… |
| FME-US-FINANCE-III-INC |
FME-US-FINANCE-III-INC |
62%
|
g for acquisitions 1,127 11,085 Other 159,062 29,020 Other current financial liabilities 1,787,373 1,675,556 Other current liabilities As of December 31, 2024 and 2023 other current liabilities… |
| FME-US-FINANCE-II-INC |
FME-US-FINANCE-II-INC |
62%
|
g for acquisitions 1,127 11,085 Other 159,062 29,020 Other current financial liabilities 1,787,373 1,675,556 Other current liabilities As of December 31, 2024 and 2023 other current liabilities… |
| FRESENIUS-MEDICAL-CARE-AUSTRALIA-PTY-LTD |
FRESENIUS-MEDICAL-CARE-AUSTRALIA-PTY-LTD |
62%
|
r exercises of put options, the Company additionally recognizes any difference between the amount of noncontrolling interests derecognized and the fair value of consideration paid within additional p… |
| FRESENIUS-MEDICAL-CARE-DEUTSCHLAND-GMBH |
FRESENIUS-MEDICAL-CARE-DEUTSCHLAND-GMBH |
62%
|
m third parties. In December 2010, the Company and Galenica Ltd. (now known as CSL Vifor) formed the renal pharmaceutical company Vifor Fresenius Medical Care Renal Pharma Ltd., an equity method inve… |
| FRESENIUS-MEDICAL-CARE-GMBH |
FRESENIUS-MEDICAL-CARE-GMBH |
62%
|
r exercises of put options, the Company additionally recognizes any difference between the amount of noncontrolling interests derecognized and the fair value of consideration paid within additional p… |
| FRESENIUS-MEDICAL-CARE-HOLDINGS-INC |
FRESENIUS-MEDICAL-CARE-HOLDINGS-INC |
62%
|
r exercises of put options, the Company additionally recognizes any difference between the amount of noncontrolling interests derecognized and the fair value of consideration paid within additional p… |
| FRESENIUS-MEDICAL-CARE-MANAGEMENT-AG |
FRESENIUS-MEDICAL-CARE-MANAGEMENT-AG |
62%
|
of property, plant and equipment, intangible assets and right-of-use assets (1) 775,274 860 528,769 1,304,903 ( 31,118 ) 42,953 1,316,738 (1) These line items are included to comply with … |
| FRESENIUS-SE-GROUP |
FRESENIUS-SE-GROUP |
62%
|
Item 5, “Operating and financial review and prospects — IV. Financial position.” For further information on the German tax authorities’ objections to our previously filed tax returns, see note 25 of … |
